Agastiya Biotech is a next-generation oncology company leveraging systems biology, immunotherapy, and quantum biophysics to develop breakthrough cancer treatments. Its lead molecule, AB001, is positioned as a first-in-class, tumor-agnostic, orally available therapeutic with the potential to transform cancer care across multiple indications.
Lead Asset: AB001
AB001 is a multi-functional small molecule cancer therapeutic with five synergistic mechanisms of action:
- • Pan-KRAS Inhibitor: Targets G12D, G12V, G13D, and G12C mutations via allosteric GDP-bound inhibition.
- • PD-L1 Immunomodulator: Blocks, degrades, and epigenetically silences PD-L1 expression.
- • Cancer Stem Cell (CSC) Dissolver: Rapidly eradicates CSC markers (CD44, ALDH1) within 24 hours.
Clinical Progress
- • Phase I (n=33 patients) completed with no dose-limiting toxicities up to 800 mg BID.
- • Biomarker reductions (CEA ↓58.6%, CA19.9 ↓42%) within 14 days.
- • PET-CT-confirmed tumor shrinkage and no organ toxicity.
- • Phase II approved in India.
Differentiators
First and only agent combining pan-KRAS inhibition, PD-L1 degradation, CSC clearance, and quantum bioactivation.
- • Tumor-agnostic efficacy.
- • Oral delivery with high tolerability.
• Strong biomarker and imaging correlation.
• Potential for orphan designation, fast track, and tumor-agnostic FDA approval pathway.
Our Programs
Anti-viral Therapeutics for Sars-Cov-2
Agastiya Biotech has studied its previously tested anti-cancer small molecule AB001 blocks Sars-CoV-2 virus therapeutics in silico studies.
Cancer Drug
Development
We are developing novel molecular formulations for breakthrough therapies in cancer stem cells, tumor supressor genes and oncogene mutations.
Psoriais
Psoriais is a chronic, immune-mediated, inflammatory relapsing systemic skin disorder that predominantly involves the skin, nails, and joints with intermittent.
Discovery Renaissance
We’re identifying the undeniable synergy between
neurons, nature and genetics overlaid
with time tested algorithms.